Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story
Top line growth momentum
continuing into 2023
Net sales by business
H1 2023, in USD bn
4.6
0.9
+8%1
4.8
1.0
+15% 1
3.6
3.7
+5% 1
H1 2022
Generics
Biosimilars
H1 2023
Note: Net sales to third parties based on carve-out financials extract. Numbers may not add up due to rounding; 1. Growth vs. H1 2022 in constant currencies. For
additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31.
22
Management Presentation
Strong volume growth of 12%
offsetting price erosion of -4%
Continued momentum of Generics
business, driven by strong growth in
Europe
Biosimilars growing double digit
without any significant launches
SANDOZView entire presentation